Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Academic Article Article uri icon

Overview

MeSH Major

  • Lipoproteins, HDL

abstract

  • For people choosing to start pharmacological prophylaxis, reduction in both LDL cholesterol and hsCRP are indicators of successful treatment with rosuvastatin.

publication date

  • April 8, 2009

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0140-6736(09)60447-5

PubMed ID

  • 19329177

Additional Document Info

start page

  • 1175

end page

  • 82

volume

  • 373

number

  • 9670